brotizolam (Lendormin) Report issue

Small molecule Experimental
AACT ChEMBL DrugBank Drug Central KEGG MeSH PubChem

Active Ingredient History

NOW
  • Now
Brotizolam is a sedative-hypnotic thienotriazolodiazepine drug which is a benzodiazepine analog. It possesses anxiolytic, anticonvulsant, hypnotic, sedative and skeletal muscle relaxant properties, and is considered to be similar in effect to other short-acting hypnotic benzodiazepines such as triazolam or midazolam. It is used in the short-term treatment of severe insomnia. Brotizolam is a highly potent and short-acting hypnotic, with a typical dose ranging from 0.125 to 0.25 milligrams, which is rapidly eliminated with an average half-life of 4.4 hours.   Wikipedia

Chemistry

  • SMILES: CC[C@H](CC[C@@H](C)[C@H]1CC[C@H]2[C@@H]3CC=C4C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C)C(C)C
  • InChIKey: KZJWDPNRJALLNS-VJSFXXLFSA-N
  • Mol. Mass: 414.72
  • ALogP: 8.02
  • ChEMBL Molecules:
    beta-sitosterol  
    brotizolam  
    angelicin  
More Chemistry

Pharmacology

Alternative names

2-bromo-4-(2-chlorophenyl)-9-methyl-6h-thieno(3,2-f)(1,2,4)triazolo(4,3-a)(1,4)diazepine | brotizolam | brotizolamum | europharma brand of brotizolam | lendorm | lendormin | lindormin | mederantil | promeco brand of brotizolam | sintonal | we 941 | we-941

Organizations (3)

Research & Development (3)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (0)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (8)

Approved Indications (1)


 

Anxiety

Experimental Indications - Clinical Trial Phases 1-4 (7)


 

Anxiety Disorders (Phase 3)

Dementia (Phase 3)

Depression (Phase 3)

Healthy Volunteers (Phase 1)

Psychophysiologic Disorders (Phase 3)

Schizophrenia (Phase 3)

Sleep Initiation and Maintenance Disorders (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 7
  • # of Trial Organizations: 3

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue